

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Previously Presented) A method for the treatment of retinopathy which comprises administering to a mammal in need of such treatment, but not having macular edema, an amount of a carbonic anhydrase inhibitor sufficient to treat retinopathy.
2. (Original) A method according to Claim 1, wherein the retinopathy comprises diabetic retinopathy.
3. (Original) A method according to Claim 2, wherein the diabetic retinopathy comprises non-proliferative diabetic retinopathy.
4. (Canceled)
5. (Previously Presented) A method according to Claim 2, wherein the diabetic retinopathy comprises preproliferative diabetic retinopathy.

6. (Previously Presented) A method according to Claim 2 for slowing the progression of diabetic retinopathy in a diabetic not suffering from diabetic retinopathy which comprises administering to said diabetic an amount of a carbonic anhydrase inhibitor sufficient to slow the progression of diabetic retinopathy.

7.-9. (Canceled)

10. (Currently Amended) A method according to ~~Claim 7~~ Claim 1, wherein the ~~vascular~~ retinopathy comprises sickle cell retinopathy.

11. (Currently Amended) A method according to ~~Claim 7~~ Claim 1, wherein the ~~vascular~~ retinopathy comprises ~~capillary occlusion or ischemia~~ retinopathy of prematurity.

12. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is administered ophthalmically to the eye or eyes.

13. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is administered systemically.

14. (Original) A method according to Claim 13, wherein the carbonic anhydrase inhibitor is administered orally.

15. (Original) A method according to Claim 13, wherein the carbonic anhydrase inhibitor is administered parenterally.

16. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is dorzolamide.

17. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is acetazolamide.

18. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is brinzolamide.

19. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is methazolamide.

20. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is ethoxzolamide.

21. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is butazolamide.

22. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is dichlorphenamide.

23. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is flumethiazide.

24. (Original) A method according to Claim 12, wherein the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, methazolamide, ethoxzolamide or brinzolamide.

25. (Original) A method according to Claim 14, wherein the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, methazolamide, ethoxzolamide or brinzolamide.

26. (Original) A method according to Claim 15, wherein the carbonic anhydrase inhibitor is dorzolamide or brinzolamide.

27. (Previously Presented) A method for the treatment of retinopathy which comprises administering to a mammal in need of such treatment, but not having macular edema, an amount of a carbonic anhydrase inhibitor sufficient to treat retinopathy, said carbonic anhydrase inhibitor being the sole active agent administered to treat retinopathy.

28. (Previously Presented) A method according to Claim 27, wherein the retinopathy comprises diabetic retinopathy.

29. (Previously Presented) A method according to Claim 28, wherein the diabetic retinopathy comprises non-proliferative diabetic retinopathy.

30. (Previously Presented) A method according to Claim 28, wherein the diabetic retinopathy comprises preproliferative diabetic retinopathy.

31. (Previously Presented) A method according to Claim 28 for slowing the progression of diabetic retinopathy in a diabetic not suffering from diabetic retinopathy which comprises administering to said diabetic an amount of a carbonic anhydrase inhibitor sufficient to slow the progression of diabetic retinopathy.

32.-34. (Canceled)

35. (Currently Amended) A method according to ~~Claim 32~~ Claim 27, wherein the ~~vascular~~ retinopathy comprises sickle cell retinopathy.

36. (Currently Amended) A method according to ~~Claim 32~~ Claim 27, wherein the ~~vascular~~ retinopathy comprises ~~capillary occlusion or ischemia~~ retinopathy of prematurity.

37. (Previously Presented) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is administered ophthalmically to the eye or eyes.

38. (Previously Presented) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is administered systemically.

39. (Previously Presented) A method according to Claim 38, wherein the carbonic anhydrase inhibitor is administered orally.

40. (Previously Presented) A method according to Claim 38, wherein the carbonic anhydrase inhibitor is administered parenterally.

41. (Previously Presented) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is dorzolamide.

42. (Previously Presented) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is acetazolamide.

43. (Previously Presented) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is brinzolamide.

44. (Previously Presented) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is methazolamide.

45. (Previously Presented) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is ethoxzolamide.

46. (Previously Presented) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is butazamide.

47. (Previously Presented) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is dichlorophenamide.

48. (Previously Presented) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is flumethiazide.

49. (Previously Presented) A method according to Claim 37, wherein the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, methazolamide, ethoxzolamide or brinzolamide.

50. (Previously Presented) A method according to Claim 39, wherein the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, methazolamide, ethoxzolamide or brinzolamide.

51. (Previously Presented) A method according to Claim 40, wherein the carbonic anhydrase inhibitor is dorzolamide or brinzolamide.